Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 35% Improvement Relative Risk Ventilation -49% ICU admission -45% c19early.org/e Goshua et al. Aspirin for COVID-19 LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? PSM retrospective 2,785 patients in the USA Lower mortality (p=0.044) and higher ventilation (p=0.037) Goshua et al., Blood, doi:10.1182/blood-2020-143349 Favors aspirin Favors control
Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
Goshua et al., Blood, doi:10.1182/blood-2020-143349
Goshua et al., Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A.., Blood, doi:10.1182/blood-2020-143349
Nov 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PSM retrospective 2,785 hospitalized patients in the USA, showing lower mortality and higher ventilation and ICU admission with aspirin treatment.
risk of death, 35.0% lower, OR 0.65, p = 0.04, treatment 319, control 319, propensity score matching, RR approximated with OR.
risk of mechanical ventilation, 49.0% higher, OR 1.49, p = 0.04, treatment 319, control 319, propensity score matching, RR approximated with OR.
risk of ICU admission, 45.0% higher, OR 1.45, p = 0.02, treatment 319, control 319, propensity score matching, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Goshua et al., 5 Nov 2020, retrospective, USA, peer-reviewed, 15 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: 332.ANTICOAGULATION AND ANTITHROMBOTIC THERAPY | NOVEMBER 5, 2020 Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis *,2 1 George Goshua, MD, Yiwen Liu, *,4 Rebecca Fine, MD, Kejal Amin, PharmD, *,8 Dayna McManus, PharmD, *,10 Chaar, MD, Matthew L. Meizlish, MSc, Eric Chang, MD, Adina Petrosan, PharmD, Hyung J. Chun, MD, 2 *,5 *,11 *,9 *,6 *,3 *,7 Yuxin Liu, MD, Cassius Ilya Ochoa *,12 Nicholas A. Defilippo, PharmD, S. Neuberg, ScD, Kent A. Owusu, PharmD, *,13 Donna Alfred Ian Lee, MD PhD 14 1 Section of Hematology, Yale University School of Medicine, New Haven, CT 2 Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 3 Yale University School of Medicine, New Haven, 4 Department of Internal Medicine, Yale University School of Medicine, New Haven, 5 Department of Pharmacy, Yale-New Haven Hospital, New Haven, 6 Section of Hematology, Yale University School of Medicine, New Haven, 7 Yale University, New Haven, CT 8 Department of Pharmacy, Yale University School of Medicine, New Havem, 9 Department of Pharmacy, Yale New Haven Hospital, New Haven, 10 Yale School of Medicine, New Haven, CT 11 Department of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT 12 University of Connecticut, Storrs, 13 Yale New Haven Hospital, New Haven, CT 14 Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT Blood (2020) 136 (Supplement 1) : 23. http://doi.org/10.1182/blood-2020-143349 Introduction: Venous thromboembolism and in-situ small vessel thrombosis are increased in hospitalized patients with COVID-19 in several patient cohorts. Endotheliopathy and activation of both platelets and coagulation predict critical illness and death. For these reasons the use of anti-platelet agents and increased-intensity anticoagulation in the care of hospitalized patients with COVID-19 is under intense study in several clinical trials. We sought to examine the impact of aspirin and anticoagulation on hospitalization outcomes. Methods: We examined outcomes in a large multi-site cohort of consecutive, hospitalized, COVID-19 laboratory confirmed patients under a risk-stratified treatment algorithm from March 13 through June 18, with a focus on efficacy of aspirin and/or increased-intensity anticoagulation. Out of 4150 identified hospitalized patients with COVID-19, we created 3 study cohorts. The overall cohort (2785 patients) excluded pediatric patients, those with incomplete electronic data, and those with multiple admissions. The aspirin (1956 patients) and anticoagulation (1623 patients) cohorts were nested within the overall cohort; the former excluded patients on any home anti-platelet therapy or those who received non-aspirin anti-platelet therapy in the hospital, while the latter excluded patients who did not receive prophylactic or intermediate dose anticoagulation in the hospital. The primary outcome was in-hospital death. Secondary outcomes were time-to-death with a competing risk (time-to-hospital-discharge), escalation to ICU, length-of-stay and use of mechanical ventilation. Variables examined included age, gender, BMI, race, Rothman Index (RI), D-dimer (DD) and patient co-morbidities including cardiovascular disease, chronic kidney disease, and prior VTE. The aspirin and anticoagulation..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit